SCHEMBL418863

SCHEMBL418863

NNS(=O)(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
ALOX12 P18054 1/20 0.50
KMT2A Q03164 1/20 0.50
NLRP1 Q9C000 1/20 0.50
ITGA1 P56199 4/20 0.49
EDNRA P25101 2/20 0.49
MCL1 Q07820 2/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
SLC40A1 Q9NP59 2/20 0.47
EDNRB P24530 1/20 0.47
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
FLT1 P17948 1/20 0.45
FLT4 P35916 1/20 0.45
KDR P35968 1/20 0.45
TRPV4 Q9HBA0 1/20 0.45
PPARG P37231 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6259655 0.86 MCL1 (0.66) MAPTMEN1KMT2AEDNRAMCL1
SCHEMBL6258831 0.82 AKR1B1 (0.44) MCL1TRPV4
SCHEMBL10993966 0.82 MEN1 (0.43) MEN1LMNAKMT2AEDNRAMCL1
SCHEMBL2371049 0.82 MEN1 (0.49) MAPTMEN1LMNAALOX12KMT2A
SCHEMBL2371055 0.82 CA12 (0.53) MAPTMEN1LMNAALOX12KMT2A
SCHEMBL6257368 0.79 TSHR (0.49) EDNRAMCL1HPGDTSHREDNRB
SCHEMBL6256510 0.79 CDK1 (0.58) MAPTLMNAMCL1HPGDTSHR
SCHEMBL962913 0.78 CA1 (0.53) LMNATSHR
SCHEMBL8530768 0.78 GUSB (0.46) MCL1HPGDTSHR
SCHEMBL29587590 0.78 CA1 (0.53) LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3670490-B1 METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES KRATON POLYMERS LLC (US) 2023-01-18 EP claimed
EP-3670490-A1 METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES Kraton Polymers LLC (US) 2020-06-24 EP claimed
US-20200165191-A1 Method of Purifying Pine Chemical Compositions from Aldehydes KRATON POLYMERS LLC (US) 2020-05-28 US claimed
EP-1320523-B1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER LAMBERT CO (US) 2005-06-22 EP claimed
US-20050004167-A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER-LAMBERT COMPANY LLC 2005-01-06 US claimed
EP-1320523-A2 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Warner-Lambert Company LLC (US) 2003-06-25 EP claimed
WO-2002024672-A2 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER-LAMBERT COMPANY LLC (US) 2002-03-28 WO claimed
CN-118184582-A 4-Seleno-1-benzenesulfonyl pyrazole compound and electrochemical synthesis method and application thereof 延安大学 2024-06-14 CN disclosed
EP-3670490-B1 METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES KRATON POLYMERS LLC (US) 2023-01-18 EP disclosed
US-10822302-B2 Method of purifying pine chemical compositions from aldehydes KRATON POLYMERS LLC (US) 2020-11-03 US disclosed
EP-3670490-A1 METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES Kraton Polymers LLC (US) 2020-06-24 EP disclosed
US-20200165191-A1 Method of Purifying Pine Chemical Compositions from Aldehydes KRATON POLYMERS LLC (US) 2020-05-28 US disclosed
US-9115065-B2 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses Kineta, Inc. (US) 2015-08-25 US disclosed
WO-2008147474-A2 SULFONYL SEMICARBAZIDES, CARBONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES SIGA TECHNOLOGIES, INC. (US) 2008-12-04 WO disclosed
EP-1827446-A2 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES SIGA TECHNOLOGIES, INC. (US) 2007-09-05 EP disclosed
WO-2006062898-A2 COMPOUNDS AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES SIGA TECHNOLOGIES, INC. (US) 2006-06-15 WO disclosed
EP-1320523-B1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER LAMBERT CO (US) 2005-06-22 EP disclosed
US-20050004167-A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER-LAMBERT COMPANY LLC 2005-01-06 US disclosed
EP-1320523-A2 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Warner-Lambert Company LLC (US) 2003-06-25 EP disclosed
WO-2002024672-A2 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER-LAMBERT COMPANY LLC (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004167-A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases BCAT1, BCAT2, ABAT MAPT 5/4885MEN1 3229/4885LMNA 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.